The Indian Patent Office on Tuesday rejected a patent application for BPaL, a combination of three medicines that has cut treatment for drug-resistant tuberculosis (TB) to six months, according to a joint statement by the groups that opposed it
The Indian Patent Office on Tuesday rejected a patent application for BPaL, a combination of three medicines that has cut treatment for drug-resistant tuberculosis (TB) to six months, according to a joint statement by the groups that opposed it
<iframe src="https://hindustansphere.com/embed/cluster/863e2d45cff495a577eaa6ac32cce1b70a64c707" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="TB Alliance fails to get patent for six-month treatment regimen"></iframe>
